Literature DB >> 23508015

Improving the success rate of gluteal intramuscular injections.

April E Boyd1, Linda L DeFord, Jeannette E Mares, Colleen C Leary, Jeana L Garris, Cecile G Dagohoy, Valentine G Boving, James P Brook, Alexandria Phan, James C Yao.   

Abstract

OBJECTIVES: This study aimed to improve the success rate of gluteal intramuscular (IM) injection.
METHODS: The outcomes of 328 intended gluteal IM injections in 115 patients receiving depot octreotide were evaluated using computed tomography performed in routine clinical practice. Patient-, nursing-, and technique-dependent factors were correlated with successful delivery of medication. Techniques associated with successful injection were taught to center nurses.
RESULTS: At baseline, 52% of injections were successfully delivered (66% men, 36% women; P = 0.001). Factors associated with successful delivery included nurses' frequency of injections (P = 0.008), landmarks use to select injection site (P < 0.001), quick needle insertion (P < 0.001), and use of nonsyringe hand to compress injection site (P < 0.001). Patient-related factors included male sex (P < 0.001), lower body mass index (P < 0.001), and lower skin-to-muscle depth at injection site (P < 0.001). Techniques associated with successful injections were then taught to center nurses. After instruction, the success rate increased from 52% to 75% (P = 0.001). Importantly, improvements were observed in both men (66%-75%; P = 0.43) and women (38%-75%; P < 0.001). Successful injection was associated with better control of flushing among those with carcinoid syndrome (P = 0.005).
CONCLUSIONS: Intended gluteal IM injections often are given into the subcutaneous space. Education in techniques associated with successful injections improves IM delivery rates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23508015     DOI: 10.1097/MPA.0b013e318279d552

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

1.  Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.

Authors:  Chan Shen; Ying Xu; Arvind Dasari; Ya-Chen Tina Shih; James C Yao
Journal:  Oncologist       Date:  2016-02-24

Review 2.  Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.

Authors:  Celeste B Burness; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.

Authors:  Muhammad Wasif Saif; Rohan Parikh; David Ray; James A Kaye; Samantha K Kurosky; Katharine Thomas; Robert A Ramirez; Thorvardur R Halfdanarson; Thomas J R Beveridge; Beloo Mirakhur; Saurabh P Nagar; Heloisa P Soares
Journal:  J Gastrointest Oncol       Date:  2019-08

Review 4.  A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry.

Authors:  Erfan Soliman; Sarujan Ranjan; Tianyou Xu; Carol Gee; Aidan Harker; Alvaro Barrera; John Geddes
Journal:  Biodes Manuf       Date:  2018-07-27

5.  Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

Authors:  Ajay Madan; Stacy Markison; Stephen F Betz; Alan Krasner; Rosa Luo; Theresa Jochelson; Jason Lickliter; R Scott Struthers
Journal:  Pituitary       Date:  2022-01-09       Impact factor: 4.107

Review 6.  Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues.

Authors:  Lowell B Anthony; Thomas M O'Dorisio
Journal:  Oncologist       Date:  2021-06-18

7.  Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.

Authors:  Beat M Jucker; Edward J Fuchs; Sarah Lee; Valeriu Damian; Paul Galette; Robert Janiczek; Katarzyna J Macura; Michael A Jacobs; Ethel D Weld; Meiyappan Solaiyappan; Ronald D'Amico; Jafar Sadik Shaik; Kalpana Bakshi; Kelong Han; Susan Ford; David Margolis; William Spreen; Manish K Gupta; Craig W Hendrix; Parul Patel
Journal:  Br J Clin Pharmacol       Date:  2021-07-31       Impact factor: 3.716

Review 8.  Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.

Authors:  Edward M Wolin; Amandine Manon; Christophe Chassaing; Andy Lewis; Laurent Bertocchi; Joel Richard; Alexandria T Phan
Journal:  J Gastrointest Cancer       Date:  2016-12

9.  Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.

Authors:  Jesse D Ortendahl; Sonia J Pulgar; Beloo Mirakhur; David Cox; Tanya Gk Bentley; Alexandria T Phan
Journal:  Clinicoecon Outcomes Res       Date:  2017-08-16

10.  Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?

Authors:  Anna Sowa-Staszczak; Marta Opalińska; Anna Kurzyńska; Karolina Morawiec-Sławek; Aleksandra Gilis-Januszewska; Joanna Palen-Tytko; Helena Olearska; Alicja Hubalewska-Dydejczyk
Journal:  Medicina (Kaunas)       Date:  2021-11-23       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.